Literature DB >> 15098177

Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history.

Barbara M Buttin1, Matthew A Powell, David G Mutch, Sheri A Babb, Phyllis C Huettner, Tina Bocker Edmonston, Thomas J Herzog, Janet S Rader, Randall K Gibb, Alison J Whelan, Paul J Goodfellow.   

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) is caused by inherited mutations in DNA mismatch-repair genes, most commonly MLH1 or MSH2. The role MSH6 plays in inherited cancer susceptibility is less well defined. The aim of this study was to investigate the penetrance and expressivity of MSH6 mutations in kindreds ascertained through endometrial cancer probands unselected for family history. Detailed pedigrees were constructed for six MSH6 mutation carriers. All reported cancers and precancers were confirmed, and tissues were obtained when available. Tumors were analyzed for microsatellite instability (MSI) and for expression of MSH2, MLH1, and MSH6. MSH6 mutation status was determined for 59 family members. Of these 59 individuals, 19 (32%) had confirmed cancers and precancers. There was an excess of mutation carriers among the 19 affected family members (11 [58%] of 19) compared with those among the 40 unaffecteds (8 [20%] of 40, P=.0065, odds ratio = 5.5, 95% CI = 1.66-18.19). In four of the seven tumors analyzed from mutation carriers other than the probands, MSI and/or MMR protein expression was consistent with the involvement of MSH6. Overall estimated penetrance of the MHS6 mutations was 57.7%. Of the tumors in mutation carriers, 78% were part of the extended HNPCC spectrum. This study demonstrates that MSH6 germline mutations are, indeed, associated with increased cancer risk and that the penetrance of mutations may be higher than appreciated elsewhere. A combination of MSI and immunohistochemistry analyses may be helpful in screening for MSH6 mutation carriers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15098177      PMCID: PMC1182090          DOI: 10.1086/421332

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  25 in total

1.  Familial endometrial cancer in female carriers of MSH6 germline mutations.

Authors:  J Wijnen; W de Leeuw; H Vasen; H van der Klift; P Møller; A Stormorken; H Meijers-Heijboer; D Lindhout; F Menko; S Vossen; G Möslein; C Tops; A Bröcker-Vriends; Y Wu; R Hofstra; R Sijmons; C Cornelisse; H Morreau; R Fodde
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

2.  hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6.

Authors:  S Acharya; T Wilson; S Gradia; M F Kane; S Guerrette; G T Marsischky; R Kolodner; R Fishel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

3.  Germ-line msh6 mutations in colorectal cancer families.

Authors:  R D Kolodner; J D Tytell; J L Schmeits; M F Kane; R D Gupta; J Weger; S Wahlberg; E A Fox; D Peel; A Ziogas; J E Garber; S Syngal; H Anton-Culver; F P Li
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

4.  Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients.

Authors:  W J de Leeuw; J Dierssen; H F Vasen; J T Wijnen; G G Kenter; H Meijers-Heijboer; A Brocker-Vriends; A Stormorken; P Moller; F Menko; C J Cornelisse; H Morreau
Journal:  J Pathol       Date:  2000-11       Impact factor: 7.996

5.  Recurrent germline mutation in MSH2 arises frequently de novo.

Authors:  D C Desai; J C Lockman; R B Chadwick; X Gao; A Percesepe; D G Evans; M Miyaki; S T Yuen; P Radice; E R Maher; F A Wright; A de La Chapelle
Journal:  J Med Genet       Date:  2000-09       Impact factor: 6.318

6.  Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations.

Authors:  Y Wu; M J Berends; R G Mensink; C Kempinga; R H Sijmons; A G van Der Zee; H Hollema; J H Kleibeuker; C H Buys; R M Hofstra
Journal:  Am J Hum Genet       Date:  1999-11       Impact factor: 11.025

7.  Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree.

Authors:  A Wagner; Y Hendriks; E J Meijers-Heijboer; W J de Leeuw; H Morreau; R Hofstra; C Tops; E Bik; A H Bröcker-Vriends; C van Der Meer; D Lindhout; H F Vasen; M H Breuning; C J Cornelisse; C van Krimpen; M F Niermeijer; A H Zwinderman; J Wijnen; R Fodde
Journal:  J Med Genet       Date:  2001-05       Impact factor: 6.318

8.  Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant.

Authors:  Maran J W Berends; Ying Wu; Rolf H Sijmons; Rob G J Mensink; Tineke van der Sluis; Jannet M Hordijk-Hos; Elisabeth G E de Vries; Harry Hollema; Arend Karrenbeld; Charles H C M Buys; Ate G J van der Zee; Robert M W Hofstra; Jan H Kleibeuker
Journal:  Am J Hum Genet       Date:  2002-01       Impact factor: 11.025

9.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.

Authors:  R Fishel; M K Lescoe; M R Rao; N G Copeland; N A Jenkins; J Garber; M Kane; R Kolodner
Journal:  Cell       Date:  1993-12-03       Impact factor: 41.582

10.  Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair.

Authors:  G T Marsischky; N Filosi; M F Kane; R Kolodner
Journal:  Genes Dev       Date:  1996-02-15       Impact factor: 11.361

View more
  24 in total

Review 1.  Lynch syndrome diagnostics: decision-making process for germ-line testing.

Authors:  E Lastra; M García-González; B Llorente; C Bernuy; M J Barrio; L Pérez-Cabornero; M Durán; C García-Girón
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

2.  Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.

Authors:  Daniel P Cahill; Kymberly K Levine; Rebecca A Betensky; Patrick J Codd; Candice A Romany; Linsey B Reavie; Tracy T Batchelor; P Andrew Futreal; Michael R Stratton; William T Curry; A John Iafrate; David N Louis
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

Review 3.  Rationale for, and approach to, studying modifiers of risk in persons with a genetic predisposition to colorectal cancer.

Authors:  Mark A Jenkins; Melissa C Southey; Graham G Giles; John L Hopper
Journal:  Curr Oncol Rep       Date:  2007-05       Impact factor: 5.075

4.  Is prostate cancer a Lynch syndrome cancer?

Authors:  Aung Ko Win
Journal:  Asian J Androl       Date:  2013-07-01       Impact factor: 3.285

5.  Association between MSH6 G39E polymorphism and cancer susceptibility: a meta-analysis of 7,046 cases and 34,554 controls.

Authors:  Zuming Li; Lihua Kong; Ling Yu; Jiao Huang; Ke Wang; Shi Chen; Miao Yu; Sheng Wei
Journal:  Tumour Biol       Date:  2014-03-13

6.  Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications.

Authors:  Aziz Zaanan; Katy Meunier; Fatiha Sangar; Jean-François Fléjou; Françoise Praz
Journal:  Cell Oncol (Dordr)       Date:  2011-04-12       Impact factor: 6.730

7.  Low prevalence of germline hMSH6 mutations in colorectal cancer families from Spain.

Authors:  Ana Sánchez de Abajo; Miguel de la Hoya; Alicia Tosar; Javier Godino; Juan-Manuel Fernández; Jose-Lopez Asenjo; Beatriz-Perez Villamil; Pedro-Perez Segura; Eduardo Diaz-Rubio; Trinidad Caldes
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

8.  Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer.

Authors:  Amanda S Bruegl; Bojana Djordjevic; Brittany Batte; Molly Daniels; Bryan Fellman; Diana Urbauer; Rajyalakshmi Luthra; Charlotte Sun; Karen H Lu; Russell R Broaddus
Journal:  Cancer Prev Res (Phila)       Date:  2014-04-25

Review 9.  Recently identified colon cancer predispositions: MYH and MSH6 mutations.

Authors:  Fay Kastrinos; Sapna Syngal
Journal:  Semin Oncol       Date:  2007-10       Impact factor: 4.929

10.  Thyroid cancer in a patient with a germline MSH2 mutation. Case report and review of the Lynch syndrome expanding tumour spectrum.

Authors:  Rein P Stulp; Johanna C Herkert; Arend Karrenbeld; Bart Mol; Yvonne J Vos; Rolf H Sijmons
Journal:  Hered Cancer Clin Pract       Date:  2008-02-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.